A Phase 2 interventional study of TollB-001 Tablet and Placebo in Systemic Sclerosis (SSc), sponsored by Toll Biotech Co. Ltd. (Beijing). Not yet recruiting at 2 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-08-04.
Sponsored by Toll Biotech Co. Ltd. (Beijing) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Scleroderma, Systemic with a site in China — 64 open to participants now, 69 under way, 4 of them phase 3. Scleroderma, Systemic · China.
Among the 82 studies in Scleroderma, Systemic with a site in China, this one is the 27th largest by planned enrollment of the 77 interventional ones that give a count, is one of 20 that started in 2026, is one of 4 in phase 2, reaches primary completion later than 41 of the 68 other live ones, and was the 80th registered.
613 studies on the registry are indexed under Scleroderma, Systemic; 221 are open to participants now.
Browse Scleroderma, Systemic studies →64 of the 82 studies in Scleroderma, Systemic with a site in China are open now. Recruiting first, the newest first:
Antengene Biologics Limited · Sites in China
Ages 18+
AstraZeneca · Sites in China, United States, Argentina and 32 more countries
Ages 5–80
Boehringer Ingelheim · Sites in China, United States, Argentina and 42 more countries
Ages 18+
Peking University Third Hospital · Sites in China
Ages 18+
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–70
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 145 Scleroderma, Systemic studies recruiting now, 83 (57%) set no upper age limit and 49 (34%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 47 · Phase 2 13 · Phase 3 7 · Phase 4 4
First in 2008; this study’s year is marked. 20 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 36 is close to the median of 37 across 449 interventional studies indexed under Scleroderma, Systemic.
Median enrollment 20 across the 77 interventional studies, 490 across the 5 observational. Of the 3 that completed or were terminated, 1 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 82 have an industry lead sponsor. The 10 most frequent:
Toll Biotech Co. Ltd. (Beijing) is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Toll Biotech Co. Ltd. (Beijing) has 1 study filed under Scleroderma, Systemic — fewer than ten, so there is no comparison to draw.
17 of the studies in Scleroderma, Systemic with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05925803Phase 3AstraZenecaDetermine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) | 2027-01-06 |
| NCT06822881Beijing GoBroad HospitalCT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc) | 2026-12-31 |
| NCT06548607Nanjing Bioheng Biotech Co., Ltd.Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases | 2026-12-31 |
| NCT07641634Prolium Bioscience, IncA Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis. | 2027-01 |
| NCT06775912Nanjing Bioheng Biotech Co., Ltd.Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases | 2027-01-01 |
Add all 17 to your calendar (.ics) → With an account.
Among the 82 studies in Scleroderma, Systemic with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this Phase II study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of TollB-001 Tablets in adults aged 18 to 70 years (male or female) with systemic sclerosis (SSc).
Study Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of TollB-001 in Adult Patients with Systemic Sclerosis (SSc) Study Design: This is a multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy, safety, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of TollB-001 in adult patients with systemic sclerosis (SSc).
Sample Size and Target Population: A total of 36 patients with SSc are planned for enrollment. Eligible patients must have a disease duration of ≤ 60 months from the first onset of non-Raynaud's phenomenon and a modified Rodnan Skin Score (mRSS) between 10 and 40 (inclusive) at the screening visit.
Study Phases: The study consists of three sequential phases:
Screening Period: Up to 28 days
Treatment Period: 90 days, comprising:
Single-Dose Phase: 3 days (dosing on Day 1 only) Multiple-Dose Phase: 87 days (consecutive daily dosing from Day 4 through Day 87, for a total of 84 days of dosing) Follow-up Period: 28 days following the last dose
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eligible participants will be randomized to receive TollB-001 tablet low dose, administered once daily for 12 consecutive weeks.
Drug: TollB-001 Tablet
Eligible participants will be randomized to receive TollB-001 tablet high dose, administered once daily for 12 consecutive weeks.
Drug: TollB-001 Tablet
Eligible participants will be randomized to receive matching placebo, administered once daily for 12 consecutive weeks.
Drug: Placebo
TollB-001 Tablets
Placebo Tablets
Rodnan Skin Score (mRSS)
Time frame: up to 12 weeks
Composite Response Index in Systemic Sclerosis (CRISS)
Time frame: up to 12 weeks
Forced Vital Capacity (FVC)
Time frame: up to 12 weeks
Health Assessment Questionnaire- Disability Index (HAQ-DI)
Time frame: up to 12 weeks
Patient Global Assessment (PtGA)
Time frame: up to 12 weeks
Incidence and Severity of Adverse Events
Time frame: up to 12 weeks
Incidence and Severity of Adverse Reactions
Time frame: up to 12 weeks
Incidence of Serious Adverse Events
Time frame: up to 12 weeks
Incidence of Serious Adverse Reactions
Time frame: up to 12 weeks
The four major vital signs, including body temperature, pulse (heart rate), respiration, and blood pressure.
Time frame: up to 12 weeks
The 12-lead electrocardiogram (ECG) includes parameters such as heart rate, RR interval, PR interval, QT interval, QRS interval, and the corrected QT interval (QTcf, where QTcf = QT / RR^0.33).
Time frame: up to 12 weeks
Routine blood test includes parameter such as white blood cell, lymphocyte count and percentage, neutrophil count and percentage, monocyte count and percentage, eosinophil count, basophil count, , red blood cell, hemoglobin, hematocrit, platelet count.
Time frame: up to 12 weeks
Blood biochemical parameters such as: aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, direct bilirubin, indirect bilirubin, total protein, albumin, alkaline phosphatase, gamma-glutamyl transferase (GGT) and urea, etc.
Time frame: up to 12 weeks
Coagulation function parameters suc as the International Normalized Ratio (INR), activated partial thromboplastin time (APTT), prothrombin time (PT), and fibrinogen.
Time frame: up to 12 weeks
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Aug 2026; primary completion for Oct 2027, 14 months later.
Of 48 phase 2 interventional studies under Scleroderma, Systemic, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 83. This study's planned 14 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TOLLB-001
Toll Biotech Co. Ltd. (Beijing)